SYK, spleen associated tyrosine kinase, 6850

N. diseases: 229; N. variants: 7
Disease: Dermatitis, Atopic ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011615
Disease: Dermatitis, Atopic
Dermatitis, Atopic 		0.030 Biomarker disease BEFREE ASN002 is an oral dual inhibitor of Janus kinase and spleen tyrosine kinase, which are involved in the pathogenesis of atopic dermatitis (AD) through their regulatory role on T helper (Th)1, Th2 and Th17/Th22 pathways. 30919407 2019
CUI: C0011615
Disease: Dermatitis, Atopic
Dermatitis, Atopic 		0.030 Biomarker disease BEFREE The Janus kinase/spleen tyrosine kinase inhibitor ASN002 significantly suppressed key AD inflammatory pathways, corresponding to clinical response. 31356921 2019
CUI: C0011615
Disease: Dermatitis, Atopic
Dermatitis, Atopic 		0.030 Biomarker disease BEFREE A review of the JAK and SYK inhibitors that are currently undergoing evaluation for efficacy and safety in the treatment of AD summarizes available data on a promising area of therapeutics and further elucidates the complex molecular interactions that drive AD. 30536048 2019